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 Introduction 
 We recently identified galectin-3 (gal-3) as a colonic 
lamina propria fibroblast (CLPF)-activating factor pro-
duced by colonic epithelial cells (CECs)  [1] . Supernatants 
of cultured primary human CECs strongly activated 
CLPF or the intestinal fibroblasts cell line CCD-18Co in-
dicated by increased NF-κB activation and IL-8 secretion. 
By a classical biochemical approach, we isolated the ma-
jor protein of the activating fast protein liquid chroma-
tography fractions from the CEC supernatants, and it was 
consecutively identified to be gal-3. Stimulation of CLPF 
with recombinant gal-3 resulted in a strong increase of 
CLPF IL-8 secretion. In further analysis, we demonstrat-
ed a downregulation of gal-3 in CLPF from Crohn’s dis-
ease (CD) fistulae and stenosis and macrophages of CD 
patients indicating a key role in inflammatory bowel dis-
ease (IBD) and mucosal inflammation  [2] .
 Gal-3 belongs to the group of β-galactoside-binding 
proteins with 14 mammalian members known  [3] . Three 
subgroups  [4] of galectins are differentiated upon their 
structures and sequences (prototype group, tandem re-
peat group and chimera group). Each galectin contains a 
unique domain of 130 amino acids which is responsible 
for the carbohydrate-binding activity, the so-called ‘Car-
bohydrate Recognition Domain’ (CRD)  [4, 5] . Gal-3 is 
the only member of the so-called ‘chimera group’ with an 
unusual prolin- and glycine-rich N-terminal domain at-
tached to the C-terminal CRD domain. The N-terminal 
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 Abstract 
 Background: We recently identified galectin-3 (gal-3) as a 
new and strong fibroblast activator produced by colonic ep-
ithelial cells. Very little is known about the influence of gal-3 
in inflammatory bowel disease. We, therefore, investigated 
the impact of gal-3 on dextran sodium sulfate (DSS)-induced 
colitis in a mouse model.  Methods: Colonic lamina propria 
fibroblasts of healthy controls were used for co-incubation 
studies of gal-3 with gal-1, TGF-β1, IFNγ, IL-4 and IL-10. Acute 
and chronic DSS colitis was induced by 3% DSS in drinking 
water in female Balb/c mice weighing 20–22 g. Recombinant 
gal-3 was expressed by the pET vector system and used for a 
5-day treatment in different concentrations intraperitoneal-
ly. The distal third of the colon was used for histologic analy-
sis. Colonic cytokine expression was determined by quantita-
tive RT-PCR.  Results: In vitro, gal-3 induced IL-8 secretion was 
significantly reduced by co-incubation with IL-10 (5 ng/ml) 
and IL-4 (10 ng/ml). Acute DSS-induced colitis was amelio-
rated by gal-3 treatment as indicated by increased colonic 
length and reduced weight loss compared to that of controls. 
In acute and chronic colitis, gal-3 treatment resulted in a sig-
nificant suppression of colonic IL-6.  Conclusion: Gal-3 signif-
icantly reduces inflammation in acute and chronic DSS colitis 
in mice indicating a potential role in intestinal inflammation. 
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was shown to lack carbohydrate-binding activity, but is 
essential for the full biological activity of gal-3  [5] . Fur-
thermore, the N-terminal domain has been implicated in 
the secretion of gal-3  [6] . The C-terminal domain in-
cludes a sugar-binding site known to be blocked by lac-
tose  [5, 7] . Galectins are expressed by a variety of cell 
types and are present both intracellularly and extracellu-
larly in a large number of tissues and cell types such as 
epithelial cells, fibroblasts, keratinocytes, osteoclasts, 
Langerhans cells, dendritic cells, monocytes and macro-
phages  [8–12] .
 The function of gal-3 self is pleiotropic including cell 
proliferation, adhesion and survival  [13–16] . Galectins 
can modulate processes such as apoptosis, cytokine secre-
tion, cell adhesion and migration  [17] and are implicated 
in the regulation, activation, differentiation and survival 
of T-cells, playing critical roles in the modulation of 
chronic inflammatory disorders such as IBDs and other 
autoimmune diseases  [18, 19] .
 Gal-3 itself protects against the formation of reactive 
oxygen products  [20] . Gal-3-transfected T-cells showed 
higher and faster growth rates compared to controls. It 
plays a role in wound healing and accelerating re-epithe-
lialization  [21] . Gal-3-deficient mice developed less in-
flammatory cell infiltrates in the peritoneal cavity after 
thioglycollate instillation compared to control mice  [22] .
 These known functions and our observation that gal-3 
is a major activator of CLPF secreted by CECs is promis-
ing to further investigate its role in the intestinal immune 
system and the pathophysiology of IBD.
 So far the potential involvement of gal-3 in IBD patho-
physiology has not been investigated into greater detail. 
We further investigated the influence of gal-3 on the in-
testinal immune functions under physiologic conditions 
and its potential role in IBD.
 Materials and Methods 
 CLPF Stimulation 
 Human CLPF of healthy controls (n = 3–5) were isolated and 
cultured as described previously  [1] . Mucosa from surgical speci-
mens was cut into 1-mm pieces, whereas biopsy specimens were 
used directly for the isolation of CLPF. Epithelial cells were sepa-
rated in Hank’s balanced salt solution without Ca 2+ and Mg 2+ 
(PAA Laboratories GmbH, Linz, Austria) with 2 m M EDTA (Sig-
ma, Deisenhofen, Germany). The remaining tissue was rinsed and 
digested for 30 min at 37   °   C with 1 mg/ml collagenase 1 (Sigma), 
0    ·     3 mg/ml DNase I (Boehringer Ingelheim, Ingelheim, Germany) 
and 2 mg/ml hyaluronidase (Sigma) in PBS (Gibco, Karlsruhe, 
Germany). Isolated cells were cultured in 25 cm 2 cell culture flasks 
(Costar, Bodenheim, Germany) with Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% FCS, penicillin (PAA Labora-
tories), streptomycin 10 mg/ml (PAA Laboratories), ciprofloxacin 
2 mg/ml (Bayer, Leverkusen, Germany), gentamycin 50 mg/ml 
(PAA Laboratories) and amphotericin B 1 mg/ml (Biochrom, Ber-
lin, Germany). Non-adherent cells were removed by subsequent 
changes of medium. The remaining cell culture contained CLPF 
and was used between passages 3 and 8. The study was approved 
by the University of Regensburg Ethics Committee.
 Galectins 
 Recombinant human gal-1 and gal-2 were purchased by R&D 
Systems, Wiesbaden, Germany.
 Recombinant Gal-3. HT-29 cells were obtained from the 
 European Collection of Cell Culture and cultured in DMEM (PAA 
Laboratories) supplemented with 10% FCS (Pan Biotech, Aiden-
bach, Germany), 1% sodium pyruvate (PAA Laboratories), 1% 
non-essential amino acids (PAA Laboratories) and 1% penicillin/
streptomycin under standard tissue culture conditions. Cells were 
cultured at 37   °   C in a 10% CO 2 atmosphere. Gal-3 was generated 
from HT-29 cells, and recombinant gal-3 was produced using the 
 pET-vector systems followed by avidin chromatography purifica-
tion (primer 5 ′ -CGGATCCAATGGCAGACAATTTTTC-3 ′ and 
5 ′ -CCAAGCTTTTTATATCATGGTATATGAAGC-3 ′ ).
 Enzyme-Linked Immunosorbent Assay 
 IL-8 ELISA was performed according to the manufacturer’s 
protocol (Biozol, Echingen, Germany).
 Mice 
 Female BALB/c mice weighing 20–22 g (Charles River, Sul-
zfeld, Germany) were used for the experiments and housed in a 
conventional facility. Animal studies were approved by the review 
board of the regional authority (‘Regierung der Oberpfalz’).
 Acute and Chronic Colitis 
 Dextran sodium sulfate (DSS) was purchased from ICN (Mr 
37,000–50,000, Eschwege, Germany). The induction of acute coli-
tis was achieved by administering 3% DSS in the drinking water ad 
libitum for 7 days. For induction of chronic colitis, BALB/c mice 
received 4 cycles of DSS treatment. Each cycle consisted of 3% DSS 
in drinking water for 7 days, followed by a 10-day interval with 
normal drinking water. In contrast to the self-limited inflamma-
tion in acute DSS colitis, which is induced by only 1 cycle of DSS 
feeding, chronic DSS-induced colitis is characterized by a self-per-
petuating chronic inflammation, which lasts for several months. 
Four weeks after the induction phase, as well as in acute colitis, 
mice were treated with gal-3 in different concentrations dissolved 
in 100 μl PBS or PBS alone (100 μl, control) intraperitoneally (i.p.) 
daily for 5 days or day 3 to day 7. Mice used for experiments were 
age matched and had received DSS treatment simultaneously.
 Measurement of Myeloperoxidase Activity 
 Colonic myeloperoxidase (MPO) activity was determined us-
ing a modified standard method. Briefly, colonic tissue was ho-
mogenized in 1 ml of 50 mmol/l potassium phosphate buffer of pH 
6.0 containing 0.5% (w/v) hexadecyltrimethylammonium hydrox-
ide, and it centrifuged at 20,000  g at 4   °   C for 20 min. Supernatant 
(10 μl) was transferred into the phosphate buffer of pH 6.0 contain-
ing 0.17 mg/ml 3,3 ′ -dimethoxybenzidine and 0.0005% H 2 O 2 . 
MPO activity of the supernatant was determined by measuring the 
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H 2 O 2 -dependent oxidation of 3,3 ′ -dimethoxybenzidine and ex-
pressed as units per gram of total protein. Total protein content of 
the samples was analyzed using a bicinchoninic acid protein assay 
kit (Sigma, Germany).
 Assessment of Histological Score 
 The distal third of the colon was removed and used for histo-
logical analysis as described before  [23] . Cross-sections of the co-
lon were fixed in 10% buffered formalin and stained with hema-
toxylin-eosin. To quantify the histological damage in intestinal tis-
sue, a previously described scoring system was applied  [24] . 
Histological analysis was performed by 2 investigators in a blinded 
fashion.
 Polymerase Chain Reaction 
 cDNA were synthesized from 1 μg total RNA using 2.5 μ M 
poly(dT), 12.5 U AMV reverse transcriptase, 0.5 m M of each 
dNTP, 5 m M MgCl 2 and 32 U RNase inhibitor in a final volume of 
20 μl (all reagents from Amersham, Biosciences). PCR was per-
formed for 40 cycles (0.5 min at 95  °  C, 0.5 min at 55  °  C, 0.5 min at 
72  °  C) in a volume of 40 μl. The reaction mixture contained 10 m M 
Tris, pH 8.3, 50 m M KCl, 2 m M MgCl2, 400 μ M of each dNTP, 1 U 
Taq DNA polymerase (all from Amersham Biosciences). Primers 
(TipMolBiol, Berlin, Germany) were added to a final concentra-
tion of 250 n M : TNFα: 5 ′ -GGC AGG TCT ACT TTG GAG TCA 
TTG C-3 ′ and 5 ′ -ACA TTC GAG GCT CCA GTG AAT TCG G-3 ′ ; 
IL-10: 5 ′ -TCC TTA ATG CAG GAC TTT AAG GGT TAC TTG-3 ′ 
and 5 ′ -GAC ACC TTG GTC TTG GAG CTT ATT AAA ATC-3 ′ ; 
IL-6: 5 ′ -TGGACTCACAGAAGGAGTGGCTAA-3 ′ and 5 ′ - TCTG
ACCACAGTGAGGAATCTCCAC-3 ′ .
 Lymph Node Preparation 
 Mesenteric lymph nodes (MLNs; pooled from each group of 
mice) were collected under sterile conditions in cold cell culture 
medium (RPMI 1640, 10% FCS, 100 U/ml penicillin and 100 μg/
ml streptomycin from GIBCO-BRL (Eggenstein, Germany) and 
3 × 10 –5  M 2-mercaptoethanol (Sigma, Deisenhofen, Germany)). 
Lymph nodes were mechanically disrupted and filtered through a 
cell strainer (70 μm). Cells (2 × 10 5 /well) were incubated in 200 μl 
culture medium for 24 h, and spontaneous cytokine secretion into 
the supernatants was measured by ELISA (all from Endogene, Wo-
burne, Mass., USA), using 4 wells per condition.
 Statistics 
 Statistical analysis was performed using the Mann-Whitney 
rank sum test or one-way analysis of variance with Bonferroni cor-
rection for more than 2 groups. Measured values are expressed as 
median ± 5th/95th percentile. Statistically significant differences 
were accepted when p value was less than 0.05.
 Results 
 IL-10 and IL-4 Reduce Gal-3-Induced IL-8 Secretion 
While TGF-β1 Increases Gal-3-Induced IL-8 
 To evaluate if further proteins are additionally in-
volved in the previously described pro-inflammatory ef-
fect of gal-3 in vitro, we performed co-incubation studies 
of gal-3 with different pro- and anti-inflammatory cyto-
kines and other galectins.
 CLPF of healthy controls were incubated with gal-3 ± 
gal-1 (10 μg/ml) or gal-2 (10 μg/ml) and pro- and anti-
inflammatory cytokines (TGF-β1 (1 ng/ml), IFNγ (1 ng/
ml), IL-4 (10 ng/ml) and IL-10 (5 ng/ml)) in different 
concentrations for 24 h. Subsequently, IL-8 secretion as a 
readout for cell activation was quantified in the superna-
tants of the cells by ELISA ( fig. 1 ). Data are given rela-
tively for stimulation with gal-3 alone.
 As demonstrated  [1] , gal-3 dose-dependently induced 
IL-8 secretion of CLPF. Co-incubation of gal-3 and gal-1 
resulted in a concentration-dependent increase of IL-8 
secretion ( fig.  1 ; no statistical significance), while gal-2 
did not further increase gal-3-induced IL-8 secretion 
(data not shown). Stimulation with gal-3 and TGF-β1 had 
a synergistic effect on IL-8 secretion reaching statistical 
significance compared to gal-3 alone ( fig.  1 ; p < 0.04), 
while IFNγ had no significant additional effect on pro-
inflammatory IL-8 secretion of gal-3 ( fig.  1 ). However, 
IL-10 (p < 0.05) and IL-4 (p < 0.002) co-incubation with 
gal-3 significantly reduced IL-8 secretion by CLPF ( fig. 1 ).
 While the IL-8 inducing effect of gal-3 was augmented 
by cytokines such as TGF-β1 – a protein with pleiotropic 
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 Fig. 1. IL-10 and IL-4 reduce gal-3 induced proinflammatory IL-8 
secretion. CLPFs were incubated with gal-3 ± gal-1 or gal-2 and 
TGF-β1, IFNγ, IL-4 and IL-10 in different concentrations for 24 h. 
IL-8 was assessed in the supernatant of the cells. Data are given rela-
tively to gal-3, n = 3–5. Gal-3 coincubated with TGF-β1 reached sta-
tistical significance (p < 0.04), besides IL-10 (p < 0.05) and IL-4 (p < 
0.002) co-incubation with gal-3 significantly reduced IL-8 secretion. 
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functions such as cell growth, wound healing or immune 
regulation – we could clearly show the cytokines such as 
IL-4 and IL-10, both known to have a protective role in 
colitis in vivo, can antagonize the IL-8 inducing effect of 
gal-3 into a more balanced direction in vitro.
 Gal-3 Reduces Inflammation in Acute DSS-Induced 
Colitis in Mice 
 To further assess the effect of gal-3 in intestinal inflam-
mation in vivo, we investigated the role of gal-3 in a 
mouse model of acute DSS-induced colitis. Gal-3 was ap-
plied i.p. in different concentrations (100, 50, 10, 1 and 
0.1 μg/ml), while PBS i.p. was used as control. Reduction 
of the colon length caused by the infiltration of inflam-
matory cells is a well-known feature of DSS colitis  [25] . 
Colon length was significantly increased in gal-3-treated 
mice compared to controls in a concentration-dependent 
manner ( fig. 2 a). Mice were monitored for clinical signs 
of colitis and differences in the course of weight loss. 
Weight loss was lower in gal-3-treated mice (gal-3 1 μg/
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ml, p < 0.001 and gal-3 0.1 g/ml, p < 0.001;  fig. 2 b). His-
tologic analysis demonstrated significantly less inflam-
mation and less tissue damage in the gal-3 groups ( fig. 2 c). 
Gal-3-treated mice had a lower score of inflammation 
compared to controls reaching statistical significance 
(100 μg/ml: 0.005; 50 μg/ml: 0.005). In contrast, MPO ac-
tivity revealed only statistical significance in animals 
treated with gal-3 0.1 μg/ml (p < 0.001), however, show-
ing decreased levels in the treatment groups, but with no 
statistical significance (data not shown). To evaluate 
whether amelioration of intestinal inflammation in gal-
3-treated animals was accompanied by modulation of cy-
tokine secretion, we compared cytokine production of 
MLN. Cytokine concentrations were measured in the su-
pernatants of MLN pooled from controls and gal-3-treat-
ed mice. IL-6 secretion was inversely correlated to gal-3 
concentration applied ( fig. 2 d). No significant differences 
were seen for the secretion of TNFα, IL-4 and IL-10 in 
controls and gal-3-treated animals (data not shown). In 
contrast to our in vitro findings, gal-3 was able to modu-
late inflammation and improve acute DSS colitis by re-
ducing pro-inflammatory cytokine secretion and inflam-
mation in the colon by modulating IL-6 secretion. To fur-
ther clarify the role of gal-3 in vivo, we investigated the 
impact of gal-3 in a chronic model of DSS-induced colitis.
 Gal-3 Improves Inflammation in Chronic 
DSS-Induced Colitis in Mice 
 In the chronic DSS colitis model, gal-3-treated mice 
displayed a concentration-dependent increase of colon 
length (with a statistical significance peak in the group 
receiving 10 μg/ml gal-3) indicating less inflammation in 
gal-3-treated animals ( fig.  3 a). MPO activity showed a 
clear decrease in the treatment groups not reaching sta-
tistical significance (data not shown). Histologic analysis 
revealed that DSS-induced inflammation was reduced in 
gal-3-treated animals compared to the control group in a 
concentration-dependent manner ( fig. 3 b; gal-3 100 μg/
ml, p < 0.001 and gal-3 50 μg/ml, p < 0.001).
 Pro-inflammatory cytokine secretion (IL-6) was sup-
pressed in gal-3-treated mice in a concentration-depen-
dent manner with lowest IL-6 levels in mice treated with 
highest gal-3 concentrations (100 μg/ml;  fig. 3 c). No sig-
nificant differences were seen for the secretion of IL-10, 
IL-4 and TNFα (data not shown). Similar to the acute 
colitis model, gal-3 was also able to reduce inflammation 
and improve histology scores in a chronic model of DSS 
colitis.
 Discussion 
 In this study, we were able to extend previous findings 
as our data show a crucial role for gal-3 in intestinal in-
flammation in vitro and in vivo. Our results show an in-
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duction of IL-8 secretion in intestinal fibroblasts by gal-3 
in vitro. In vivo, in 2 animal models of intestinal inflam-
mation, gal-3 has a protective and anti-inflammatory po-
tential.
 The induction of IL-8 secretion by gal-3 was in-
creased upon co-incubation with TGF-β1, while IL-4 
and IL-10 were able to antagonize the gal-3 effect on 
IL-8 secretion.
 Using the DSS model of colitis, we were able to show a 
protective role of gal-3 in both acute and chronic inflam-
mation. Significant reduced signs of inflammation were 
detected in the acute DSS model of colitis with increased 
colon length as a sign of lesser inflammation in gal-
3-treated mice. Furthermore, gal-3 treatment improved 
colitis in the chronic DSS model. Gal-3 has extensively 
been studied in various kinds of inflammation with con-
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trary findings so far. In several studies, it was demonstrat-
ed that gal-3 might act as chemoattractant for dendritic 
cells or macrophages or can have an impact on the prolif-
eration of activated T lymphocytes  [26, 27] . Contrary to 
that, in fungal infections, gal-3 was shown to have a pro-
tective role  [28] . In another model of infection, gal-3 was 
protective by a negative regulation of IL-17A responses 
through inhibition of IL-23/IL-17-axis cytokine produc-
tion by dendritic cells  [29] . Gal-3 was shown to have an 
inhibitory effect on monocyte migration and apoptosis 
 [30] . However, infection with  C. rodentium was only a 
minor effect in gal-3 null mice with delayed T-cell, mac-
rophage and dendritic cells infiltration in the intestinal 
mucosa  [31] . Our findings indicate a clear protective role 
of gal-3 with significant reduction of intestinal inflamma-
tion in a model of colitis.
 Gal-3 seems to be protective in vivo by modulating 
IL-6 secretion. IL-6 is involved in a different kind of in-
flammation and in the regulation of the humoral im-
mune system. In a mouse model, IL-6 has been shown 
to be a key player in TH1-mediated colitis while antago-
nizing IL-6 significantly improved colitis  [32] . In hu-
mans, tocilizumab, a humanized anti-IL-6 receptor an-
tibody, is already approved in the therapy of rheumatoid 
arthritis  [33] and other autoimmune diseases  [34] . A pi-
lot study with tocilizumab in patients with CD has al-
ready indicated good tolerance, improved disease activ-
ity and effectiveness  [35] , and tocilizumab is expected to 
be approved in the therapy of CD with newer data in the 
near future. These data and our findings indicate a cen-
tral role for IL-6 in inflammation in IBD while targeting 
or suppression of this interleukin results in improved 
colitis.
 Our observation is in agreement with previous find-
ings in humans showing that gal-3 was reduced in active 
colitis while being elevated in patients with no clinical 
manifestations confirming a protective role of gal-3 in in-
testinal inflammation  [36] . In active CD, gal-3 expres-
sion is decreased in the inflamed epithelium  [37] . Gal-3 
expression could be reduced by TNF incubation in the 
colonic adenocarcinoma cell line HCT-8  [37] . TNF cer-
tainly is an important mediator of IBD-associated inflam-
mation. However, in CLPF, we found a synergistic effect 
of TNF α and gal-3. Other galectins such as gal-2 have 
been shown to induce T-cell apoptosis or modulate 
monocyte or macrophage functions  [30, 38] . In experi-
mental colitis, gal-2 was shown to be able to improve 
acute and chronic colitis showing a clear role of galectins 
in inflammation and modulation of the immune system 
 [39] .
 A substantially higher percentage of sera from CD 
patients contained anti-gal-3 IgG autoantibodies than 
from those with ulcerative colitis and healthy controls. 
In CD patients, the titer of autoantibodies negatively 
correlated with disease activity  [40] . This result was con-
firmed recently and gal-3 was shown to modulate T-cell 
function in IBDs  [41] . Beside, in human dendritic cells, 
gal-3 is capable of inhibiting T-cell activation. Knock 
down of gal-3 in dendritic cells was followed by in-
creased IFNγ and reduced IL-10 expression  [42] . Fur-
thermore, gal-3 is able to influence TH17, a key player 
in tissue inflammation, by modulating cytokine secre-
tion of dendritic cells  [43] . Our study now provides evi-
dence that gal-3 is able to modulate and improve colitis. 
Gal-3 showed a suppression of IL-6, indicating a TH1-
mediated suppression of inflammation in this model of 
colitis. These findings are in accordance with published 
data where gal-3 was capable to suppress T-cell respons-
es  [44] .
 To use a DSS model of colitis is widely accepted due to 
its simplicity and its similarity to human disease. How-
ever, a chemical induced model of colitis can never com-
pletely reflect the complexity of human disease, and the 
inherent differences between mice and humans need to 
be kept in mind. Therefore, further analysis of gal-3 in 
humans is warranted. Besides, the role and impact of 
 gal-3 in other animal models of colitis need to be eluci-
dated, since it is well known that they all use a different 
approach to inflammation (e.g. gene knockout, transgen-
ic, chemical, adoptive transfer and spontaneous). These 
models will be helpful to further clarify the role of gal-3 
in inflammation and to give a more detailed inside in the 
exact pathways used by gal-3 and to confirm our findings 
of a more TH1-balanced modulation of inflammation 
 [45] .
 In summary, we have demonstrated an in vivo model 
of acute and chronic colitis with a clear protective and key 
role of gal-3 and significant amelioration of intestinal in-
flammation. We could demonstrate that the gal-3 effect 
is mediated via modulation of IL-6.
 Further investigations of gal-3 are warranted to under-
line the key role of gal-3 in inflammation and epithelial 
stabilization, to further characterize the subset of T-cells 
responsible for the protective effect of gal-3 and its poten-
tial role in IBDs.
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